Apollo signs license option deal with Case Western to develop point-of-care blood analyzer

NewsGuard 100/100 Score

A blood test yields a wealth of information crucial to a person's health. What's needed is a device that is small and inexpensive, yet capable of quickly providing a thorough analysis using a very small sample.

With a two-year option license agreement from Case Western Reserve University's Technology Transfer Office (TTO), Apollo Medical Devices LLC (Apollo) plans to further advance toward commercialization a point-of-care blood tester to fill that need.

An option agreement allows time for a company to demonstrate it can make a technology commercially viable by proof of concept and attracting investment.

Apollo emerged from the Laboratory for Biomedical Sensing, part of Case Western Reserve's Department of Biomedical Engineering. The company will further develop a hand-held medical device that, with one drop of blood, can determine several health factors.

"This will be used, for example, by diabetic patients to test their glucose (blood sugar)," said Wayne Hawthorne, senior licensing manager with TTO. "It could be for other people who have deficiencies in potassium. It could be for renal dialysis."
"What we have is a functional prototype," said Apollo Chief Executive Officer Patrick Leimkuehler. "We plan to redesign the tester to feature a built-in display screen and make other adjustments."

Apollo, formed in October 2014, is quickly making progress and garnering financial support. In the past month, the company was awarded three grants, totaling more than $150,000, to help fund product development. The funding was provided by MAGNET (Manufacturing Advocacy & Growth Network), The Innovation Fund, which backs Northeast Ohio's startups with pre-seed funds, and the Ohio Third Frontier program, which announced a $100,000 grant. Apollo also is a client of JumpStart's Burton D. Morgan Mentoring Program.

Biomedical Engineering Associate Professor Miklos Gratzl, who leads the Laboratory for Biomedical Sensing, said Apollo seeks to fill a market need for a blood test that produces results within five minutes and requires only a drop of blood from a finger prick, rather than blood drawn from a vein.

The blood tester, or analyzer, weighs less than a pound and measures about 3 inches wide and 4 inches high. A blood sample can be placed on a disposable cartridge in a slot at the top.

In pre-clinical tests, blood-test results are being compared with results of traditional methods.

Punkaj Ahuja, Apollo's founder and chief technology officer, is a graduate student in biomedical engineering in the Laboratory for Biomedical Sensing. He became fascinated with the technology while transitioning from undergraduate to graduate studies at Case Western Reserve about five years ago.

Ahuja said the primary market for the product would be hospital emergency rooms and urgent-care medical centers. "That is where time really matters the most in improving patient outcomes," he said.

Ahuja said the device would also be useful in outpatient clinics, primary care physician offices and nursing homes. He also envisions use in the military or by first responders involved in disaster relief.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Red light therapy shown to significantly reduce blood sugar spikes, study finds